<div id="readability-page-1"><p>Wedbush analyst Martin Fan reiterated a Buy rating on IMAX today and set a price target of $46.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>According to TipRanks, Fan is a 4-star analyst with an average return of <span>41.9%</span> and a 75.00% success rate. Fan covers the Healthcare sector, focusing on stocks such as Zenas BioPharma, Inc., Oruka Therapeutics, and Fate Therapeutics.</p> <p>In addition to Wedbush, IMAX also received a Buy from B. Riley Securities’s Drew Crum in a report issued today. However, on November 25, Goldman Sachs upgraded IMAX (NYSE: IMAX) to a Hold.</p></div>

IMAX

<p>Wedbush analyst Martin Fan reiterated a Buy rating for IMAX with a $46 price target. Fan is a 4-star analyst with a 41.9% average return and 75% success rate. B. Riley Securities also rated IMAX as Buy, while Goldman Sachs upgraded it to Hold on November 25.</p>

Wedbush Sticks to Their Buy Rating for IMAX (IMAX)